Partner
Kassandra represents pharmaceutical patent holders in litigations arising under the Hatch-Waxman Act as well as parties in trade secret misappropriation actions. Her experience covers numerous aspects of trial preparation, including conducting offensive and defensive discovery, taking and defending fact and expert depositions, managing day-to-day litigation activities, preparing for and going to trial, and drafting post-trial briefing. Kassandra has also counseled clients regarding quarantine and clean-room redesign procedures.
Kassandra represents clients in inter partes review (IPR) and other contested proceedings before the PTAB. Her experience includes developing validity positions, drafting written submissions, and preparing technical expert witnesses. Kassandra has an active patent prosecution and counseling practice, preparing and prosecuting U.S. patent applications on behalf of international clients, with a focus on chemical subject matter, including pharmaceutical and veterinary drug products.
While in law school, Kassandra worked as a legal extern for a medical device company, where she conducted patent portfolio analysis and mapped competitors' technologies in order to formulate patent strategies. In addition, Kassandra aided in developing the Maurer School of Law Intellectual Property Clinic, where she provided patent due diligence and patent drafting services for several clients.
Kassandra's pro bono experience includes assisting veterans with claims before the U.S. Court of Appeals for Veterans Claims and the U.S. Court of Appeals for the Federal Circuit.
Lannett Holdings, Inc. v. AstraZeneca AB
Member of team that defended patent owner in two IPRs relating to Zomig® Nasal Spray, leading to non-institution decisions in both proceedings.
IPR2015-01629, -01630, PTAB
AstraZeneca AB v. Aurobindo Pharma, Ltd.
Member of team that represented AstraZeneca in Abbreviated New Drug Application (ANDA) litigation against multiple generic challengers on its Onlgyza® and Kombiglyze® XR pharmaceutical drug products. Patent sustained in district court. Patent sustained in district court and parallel inter partes review (IPR) proceeding.
1:14-cv-00664, D. Del., Judge Sleet
IPR2015-01340, PTAB, Judges Elluru, Paulraj, Tierney
Coalition for Affordable Drugs V LLC v. Biogen MA Inc.
Member of team that defended client in three inter partes reviews (IPR) relating to Tecfidera®, leading to non-institution decisions in the first two proceedings and a final decision confirming patentability in the third proceeding.
IPR2015-01086, -01136, -01993, PTAB, Judges Gardener-Lane, Katz, Schafer
Smith & Nephew v. ConforMIS, Inc.
IPR2016-01874; IPR2017-00115, -00307, -00372, -00373, -00487, -00488, -00510, -00511, -00544, -00545, -00778, -00779, -00780, -00983, -00984, PTAB, Judges Bunting, Scanlon, Weiker, Worth
AbbVie Inc. et al v. Alvotech hf.
1:21-cv-02258, 1:21-cv-02899, N.D. Ill., Judge Lee
E. I. du Pont de Nemours v. Synvina C.V.
Represented DuPont and ADM in a successful Federal Circuit appeal from an IPR proceeding, resulting in reversal of the PTAB’s decision and invalidation of all challenged claims of Synvina’s patent directed to production of 2,5-furan dicarboxylic acid.
17-1977, Fed. Cir.
Articles
Strategic Intellectual Property Considerations for Protecting AI Innovations in Life Sciences Strategic Intellectual Property Considerations for Protecting AI Innovations in Life Sciences
January 2023
International Pharmaceutical IndustryIP Health Blog
Considerations for Protecting Trade Secrets in FDA Correspondence Considerations for Protecting Trade Secrets in FDA Correspondence
April 12, 2022
Articles
Key Insights from the PTAB’s Updated Orange Book and Biologic Patent Study Key Insights from the PTAB’s Updated Orange Book and Biologic Patent Study
August 30, 2021
IP WatchdogArticles
Client-Attorney Privilege in the U.S. Client-Attorney Privilege in the U.S.
December 1, 2017
CIPA JournalPress Release
32 Finnegan Attorneys Recognized by Best Lawyers 32 Finnegan Attorneys Recognized by Best Lawyers
August 17, 2023
Best LawyersDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.